Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

Kalkine IPO Report

Is this the right time to exit from Picard Medical Inc (PMI)?

Oct 09, 2025

Company Overview

Picard Medical, Inc. (PMI) serves as a holding company fully owning SynCardia Systems, LLC, a medical technology firm focused on the SynCardia Total Artificial Heart (TAH)—the sole FDA- and Health Canada-approved implantable TAH, with over 2,100 units implanted across 27 countries as a bridge to transplantation for biventricular heart failure patients. The system includes artificial ventricles, external pneumatic drivers for hospital and home use, and drivelines, implanted via standard surgical methods to deliver pulsatile flow. The company's roadmap involves enhancing driver technology, broadening indications to Bridge to Candidacy and long-term use (two years+), expanding globally, and pioneering the fully implantable Emperor TAH as a transplant alternative, with prototypes in testing, animal studies slated for early 2025, and potential FDA approval by 2028. Facing competitors like Carmat's Aeson TAH, BiVACOR's clinical trials, and off-label LVAD combinations, Picard emphasizes its clinical expertise, intellectual property, and advantages in mechanical circulatory support. In 2025, it pursued an NYSE IPO to secure approximately USD 17 million for growth and innovation.

Initial Public Offering

The company launched its IPO on August 29th, 2025, under the ticker PMI and had sold approximately 4,250,000 shares at USD 4.00 share. We had covered this IPO in our ‘Kalkine IPO Report’ on August 18, 2025, and had concluded that this IPO was “Attractive” given it given the financial performance of the company, use of proceeds, and associated risks.

Conclusion

The closing price of $9.60 for Picard Medical, Inc. (NYSE American: PMI) (October 8, 2025) offers IPO investors a 140.00% price surge from the $4.00 IPO price. This realized return is a key factor. However, the company faces deepening financial weaknesses. Despite revenue growth, the net loss increased to $6.72 million, driven by non-cash charges. Crucially, gross profit turned negative, signaling rising costs and financial strain. Given the significant surge from the IPO price and the growing financial risks, investors who participated in the IPO can consider exiting their position at the closing price of $9.60 as on October 08, 2025.

*The reference data in this report has been partly sourced from Refinitiv.


Disclaimer-

This report (“Report”) has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any advice provided in this Report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred in this Report. You should obtain a copy of the relevant Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any of the general advice in this Report or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its reports (including this Report), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Report does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products. Our reports contain general recommendations to invest in securities and other financial products. Kalkine is not responsible for, and does not guarantee, the performance of, or returns on, any investments mentioned in this Report.

Kalkine does not issue, sell or deal in any financial products.

This Report may contain information on past performance of particular investments. Past performance is not a reliable indicator of future performance. Returns stated do not take into account transaction costs and taxes. To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Report, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you.  To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information. Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Report or on the Kalkine website. Any such employees and associates are required to comply with certain, procedures and disclosures as required by law.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website including entities covered in this Report.

Copyright 2025 Krish Capital Pty. Ltd. (ABN 61629651510). All Rights Reserved. No part of this report, or its content, may be reproduced in any form without our prior consent.

Past performance is not a reliable indicator of future performance.

Support

Hi! How can we help you today?

Loading…